Cyclerion Therapeutics (NASDAQ:KRSA) Coverage Initiated by Analysts at Guggenheim

Guggenheim started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $70.00 price objective on the stock.

Several other research firms have also commented on KRSA. Stifel Nicolaus initiated coverage on Cyclerion Therapeutics in a research report on Monday, September 14th. They issued a “buy” rating and a $43.00 price objective on the stock. UBS Group assumed coverage on Cyclerion Therapeutics in a research report on Friday, September 11th. They issued a “buy” rating and a $55.00 target price for the company. Zacks Research upgraded Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. Finally, TD Cowen assumed coverage on Cyclerion Therapeutics in a report on Monday, September 14th. They set a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Cyclerion Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Cyclerion Therapeutics Trading Down 0.5%

NASDAQ:KRSA opened at $30.83 on Monday. Cyclerion Therapeutics has a twelve month low of $7.19 and a twelve month high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.